uniQure Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 221

Employees

  • Stock Symbol
  • QURE

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $23.80
  • (As of Friday Closing)

uniQure General Information

Description

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Contact Information

Website
www.uniqure.com
Formerly Known As
Amsterdam Molecular Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Paasheuvelweg 25a
  • 1105 BP Amsterdam
  • Netherlands
+31 020
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Life Sciences
Corporate Office
  • Paasheuvelweg 25a
  • 1105 BP Amsterdam
  • Netherlands
+31 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

uniQure Stock Performance

As of 13-Nov-2026, uniQure’s stock price is $23.80. Its current market cap is $1.67B with 70.1M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$23.80 $24.63 $8.73 - $51.72 $1.67B 70.1M 2.21M -$3.51

uniQure Financials Summary

As of 30-Sep-2026, uniQure has a trailing 12-month revenue of $20.2M.

In Thousands,
USD 		TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 928,392 862,549 493,159 (196,932)
Revenue 20,167 16,098 27,119 15,843
EBITDA (184,186) (133,554) (182,160) (272,662)
Net Income (232,897) (198,971) (239,556) (308,478)
Total Assets 940,551 824,908 556,536 831,689
Total Debt 62,367 63,393 66,061 138,409
Public Fundamental Data provided by Morningstar, Inc. disclaimer

uniQure Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore uniQure‘s full profile, request access.

Request a free trial

uniQure Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other
Biotechnology
Amsterdam, Netherlands
221 As of 2025

Waltham, MA
 

Richmond, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

uniQure Competitors (63)

One of uniQure’s 63 competitors is Dyne Therapeutics, a Formerly VC-backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dyne Therapeutics Formerly VC-backed Waltham, MA
Sangamo Therapeutics Formerly VC-backed Richmond, CA
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Alector Formerly VC-backed South San Francisco, CA
Taysha Gene Therapies Formerly VC-backed Dallas, TX
You’re viewing 5 of 63 competitors. Get the full list »

uniQure Patents

  • 165

    Total Documents Applications and Grants

  • Total Patents Families

  • 41

    Granted

  • 85

    Pending

  • Expiring in next 12 mo

uniQure Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260061079-A1 Bbb interacting capsids Pending 22-Aug-2024
WO-2026041788-A1 Novel bbb interacting capsids Pending 22-Aug-2024
WO-2026041782-A1 Novel raav capsids Pending 22-Aug-2024
US-20260125704-A1 Raav capsids Pending 22-Aug-2024
AU-2025256404-A1 Nucleic acid for a1at regulation Pending 19-Apr-2024 C12N15/113
To view uniQure’s complete patent history, request access »

uniQure Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

uniQure Investments & Acquisitions (5)

uniQure’s most recent deal was a Corporate Asset Purchase with Apic Bio (Global Rights for the Development and Commercialization of APB-102) for . The deal was made on 31-Jan-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Apic Bio (Global Rights for the Development and Commercialization of APB-102) 31-Jan-2023 Corporate Asset Purchase Buildings and Property
Corlieve Therapeutics 30-Jul-2021 Merger/Acquisition Drug Discovery
UniQure (Intellectual Property in Amsterdam, Netherlands) 17-Apr-2017 Corporate Asset Purchase Buildings and Property
InoCard 31-Jul-2014 Merger/Acquisition Biotechnology
AMT (Biotechnology) 06-Apr-2012 Merger/Acquisition Biotechnology
To view uniQure’s complete investments and acquisitions history, request access »

uniQure ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.01 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,585

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view uniQure’s complete esg history, request access »

uniQure Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
InoCard Heidelberg, Germany 2014
HEMGENIX King of Prussia, PA

uniQure FAQs

  • When was uniQure founded?

    uniQure was founded in 1998.

  • Where is uniQure headquartered?

    uniQure is headquartered in Amsterdam, Netherlands.

  • What is the size of uniQure?

    uniQure has 221 total employees.

  • What industry is uniQure in?

    uniQure’s primary industry is Biotechnology.

  • Is uniQure a private or public company?

    uniQure is a Public company.

  • What is uniQure’s stock symbol?

    The ticker symbol for uniQure is QURE.

  • What is the current stock price of uniQure?

    As of 13-Nov-2026 the stock price of uniQure is $23.80.

  • What is the current market cap of uniQure?

    The current market capitalization of uniQure is $1.67B.

  • What is uniQure’s current revenue?

    The trailing twelve month revenue for uniQure is $20.2M.

  • Who are uniQure’s competitors?

    Dyne Therapeutics, Sangamo Therapeutics, Sarepta Therapeutics, Alector, and Taysha Gene Therapies are some of the 63 competitors of uniQure.

  • What is uniQure’s annual earnings per share (EPS)?

    uniQure’s EPS for 12 months was -$3.51.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process